Clinical trials: Heart Transplant Rejection
Transplant Failure, Heart Transplant Rejection
MuLtimodality EvaluatiOn of aNtibody mEdiated Damage in Heart Transplantation (LEONE-HT)
Cross-sectional evaluation of antibody mediated injury in heart transplantation patients through a multimodal approach: electron microscopy, optic microscopy, immunohistochemistry techniques, transthoracic echocardiography…
- Conditions
- Transplant Failure, Heart Transplant Rejection, Antibody-mediated Rejection
- Trial name
- LEONE-HT (NCT05184426)
- Testing
- Echocardiogram, Cardiac magnetic resonance, Coronary angiography
- Where
- 3 sites in Spain
- Volunteers
- 90 people
- Sponsor
- Juan Francisco Delgado Jimenez
Heart Transplant Failure and Rejection
A Comparative Effectiveness Study in Heart Transplant Patients of Rejection Surveillance With Cell-free DNA Versus Endomyocardial Biopsy
This is an open label Comparative Effectiveness Research (CER) study in which patients will be randomized at the site level to Prospera surveillance or EMB surveillance in a 2:1 ratio (Prospera to EMB) at each site.
- Trial name
- ACES-EMB (NCT06414603)
- Testing
- The Prospera™ Test
- Where
- 16 sites in United States
- Volunteers
- 250 people
- Sponsor
- Natera, Inc.
Cardiac Transplant Rejection
A Study of AI in Cardiac Transplant in Echocardiographic Analysis (ORACLE)
The purpose of this research is to detect episodes of rejection versus non-rejection after cardiac transplant and the diagnostic accuracy of an Artificial Intelligence (AI) algorithm using the data from an ECG (electrocardiogram)…
- Trial name
- ORACLE (NCT06178744)
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Mayo Clinic
Heart Transplant
Noninvasive Methods to Monitor Graft Survival in Heart Transplant Patients
Injury of transplant tissue by a transplant recipient's immune system continues to be the leading cause of graft rejection and recipient death.
- Trial name
- NCT00466804
- Testing
- Heart transplant
- Where
- 12 sites in United States
- Volunteers
- 263 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Immunosuppression
Safety Outcomes of Lower Immunosuppression Versus Traditional Immunosuppression in Heart Transplant Recipients
This was a study to compare less intense immunosuppression with a more traditional approach. The hypothesis was that less immunosuppression will provide similar protection against rejection than typical 2-3 drug therapy.
- Trial name
- TICTAC (NCT00299221)
- Testing
- Tacrolimus, combination therapy
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- Newark Beth Israel Medical Center
Heart Transplant Rejection
Cardiac Magnetic Resonance Imaging (CMRI) for Detection of Cardiac Transplant Rejection
To find a non-invasive alternative (with using cardiac MRI) to invasive endomyocardial biopsies for serial detection (EMB) and follow-up of cellular rejection in heart transplant in childhood.
- Trial name
- NCT01136135
- Testing
- CARDIAC MRI
- Where
- France
- Volunteers
- 36 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cardiac Transplantation
Absolute Myocardial Perfusion Measurement in the Transplanted Heart
The goal of this study is to detect AR and CR in the transplanted heart by quantitative assessment of myocardial blood flow and its constituents by myocardial contrast echocardiography (MCE).
- Trial name
- NCT00414895
- Where
- Switzerland
- Volunteers
- 90 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Antibody-mediated Rejection, Hyperacute Rejection of Cardiac Transplant
The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation
All individuals who receive a heart transplant are at risk for developing antibody-mediated rejection (AMR). An antibody is a protein produced by the body's immune system when it detects a foreign substance, called an antigen.
- Conditions
- Antibody-mediated Rejection, Hyperacute Rejection of Cardiac Transplant, Left Ventricular Dysfunction, Cardiac Allograft Vasculopathy
- Trial name
- DUET (NCT02013037)
- Testing
- Eculizumab
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Cedars-Sinai Medical Center
Heart Transplant Rejection, Immune Suppression
Mobile Video Directly Observed Therapy (DOT) for Immunosuppression Medication Adherence in Adolescent Heart Transplant Recipients
We will conduct a two-group randomized controlled trial to examine the eMocha DOT intervention with pediatric HT recipients.In this population, medication nonadherence remains a primary cause of late acute rejection (LAR)…
- Conditions
- Heart Transplant Rejection, Immune Suppression, Pediatric Heart Transplant, Medication Nonadherence
- Trial name
- NCT05732779
- Testing
- DOT intervention
- Where
- 4 sites in United States
- Volunteers
- 100 people
- Sponsor
- University of Florida
Heart Transplantation
SCHEDULE Follow Up Visit 5-7 yr
The major aim of this extension study was to evaluate the long-term effect (i.e. 5 to 7 years) of early initiation of everolimus and early elimination of CsA compared to standard immunosuppressive regimen including CsA on primary…
- Trial name
- CRAD001ANO05 (NCT02864706)
- Testing
- Everolimus, Cyclosporine, Mycophenolate mofetil
- Where
- 6 sites in Denmark, Norway and 1 more
- Volunteers
- 95 people
- Sponsor
- Novartis Pharmaceuticals
Heart Transplantation, Heart Transplant Rejection
A National Swedish Study Evaluating Dd-cfDNA for as a Diagnostic Biomarker for Rejection Surveillence in Heart Transplantation
The SweD-HTx-study is an observational, multicenter cohort study including adult HTx recipients from Skåne University Hospital (Lund), Sahlgrenska University Hospital (Gothenburg), and Karolinska University Hospital (Stockholm).
- Trial name
- SweD-HTx (NCT07531784)
- Testing
- dd-cfDNA
- Where
- Sweden
- Volunteers
- 120 people
- Sponsor
- Karolinska Institutet
CMV Viremia, Heart Transplant Infection
Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant
The purpose of this study is to compare the safety and efficacy of letermovir with valganciclovir for prevention of Cytomegalovirus (CMV) viremia in moderate to high risk serostatus heart transplant recipients.
- Conditions
- CMV Viremia, Heart Transplant Infection, Heart Transplant Failure and Rejection
- Trial name
- VALET-CMV (NCT07079735)
- Testing
- Letermovir, Valganciclovir
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- Columbia University